Medicine Recommendations

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Depressive illness

Chronic Neuropathic Pain

Treatment and prophylaxis of schizophrenia

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Rapid tranquilization

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Parkinson’s disease – adjunctive therapy in adults with end-of-dose motor fluctuations who cannot be stabilised on preparations of levodopa/DOPA decarboxylase inhibitors

Anxiety (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of epilepsy

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Pain

Restless Legs Syndrome

Chronic pain

For cluster headaches - under review

Schizophrenia

MHRA Drug Safety Update - Risperidone and paliperidone: risk of floppy iris syndrome

Maintenance treatment of schizophrenia in adult patients

Treatment of schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products

Various indications - see Palliative Care Clinical Practice Summary Guidance

Pain

Pain

Depressive illness, post-traumatic stress disorder, obsessive compulsive disorder, panic disorder, social phobia, generalised anxiety disorder